Houston, TX – A new study has just been released highlighting the advantages that Sonablate can offer veterans suffering from prostate cancer. The study, conducted at the Michael E. DeBakey Veterans Affairs Medical Center, demonstrates that high-intensity focused ultrasound (HIFU) using the Sonablate platform provides comparable oncologic, erectile, and urinary outcomes to standard-of-care options for localized prostate cancer
Titled “High-Intensity Focused Ultrasound Ablation for Primary or Salvage Prostate Cancer Therapy: Initial Outcomes in the Veteran Healthcare Setting,” the study is the initial and largest retrospective case series of HIFU use for primary and salvage treatments of localized prostate cancer in US veterans.
The study's authors conclude that HIFU is a promising treatment option for localized prostate cancer, and as they accumulate more long-term data and experience, HIFU may become an increasingly important tool against prostate cancer, offering veterans a less invasive option that balances oncological control with quality-of-life preservation.
Sonablate® HIFU is approved in more than 50 countries worldwide and was the first focused ultrasound device to be FDA-cleared in the U.S. for the ablation of prostate tissue. This innovative solution for prostate diseases has allowed Sonablate® HIFU to become the industry leader in focal therapy. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
Sonablate is a registered trademark of Sonablate Corp. © 2024 Sonablate Corp. All rights reserved.
